Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Coherus BioSciences is a leading biosimilar company that develops and commercializ...
Coherus BioSciences is a leading biosimilar com...
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology comp...
Amicus Therapeutics (Nasdaq: FOLD) is a global,...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company th...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a ...
A global leader in DNA sequencing and array-based technologies, Illumina is fuelin...
A global leader in DNA sequencing and array-bas...
Global Cancer Technology (GCT) is an emerging medical technology company with nu...
Global Cancer Technology (GCT) is an emerging...
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the ...
Motus GI Holdings, Inc. is a medical technology...
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therap...
AGTC is a clinical-stage biotechnology company ...
Join the National Investor Network and get the latest information with your interests in mind.